Mydriaticum (Tropicamide)

Tropicamide, the active ingredient in Mydriaticum, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It induces pupil dilation and cycloplegia, facilitating eye examinations and certain diagnostic procedures. GNH USA supplies Mydriaticum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tropicamide acts on the muscarinic receptors of the iris and ciliary body, providing mydriasis and cycloplegia for various ophthalmic indications. - Induction of mydriasis: dilates the pupil to allow detailed retinal and fundus examination. - Cycloplegia for diagnostic procedures: temporarily paralyzes accommodation to assess refractive errors. - Adjunct in treatment of anterior uveitis: helps reduce pain and photophobia by immobilizing the iris muscle.

Tropicamide is generally well tolerated, but ocular and systemic reactions can occur.

Common Side Effects: - Transient stinging or burning upon instillation. - Blurred vision lasting several hours. - Photophobia due to enlarged pupil. - Mild increase in intraocular pressure. - Temporary redness of the eye.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Allergic reactions such as rash or edema. - Systemic anticholinergic effects (dry mouth, tachycardia). - Persistent mydriasis beyond the expected duration. - Severe ocular pain or inflammation.

When using Tropicamide, consider the following safety measures. - Assess intraocular pressure: screen for glaucoma before administration. - Avoid in patients with known hypersensitivity to tropicamide or other anticholinergics. - Use cautiously in eyes with narrow anterior chamber angles. - Monitor elderly or pediatric patients for systemic anticholinergic signs. - Store at room temperature: keep in the original container, protect from light and moisture.

Tropicamide may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use with other mydriatics (e.g., phenylephrine): additive dilation may precipitate angle‑closure glaucoma. - Systemic anticholinergics (e.g., atropine): increased anticholinergic load can heighten systemic effects. - Combined cycloplegics and glaucoma medications: may mask intraocular pressure changes.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may enhance corneal absorption of tropicamide. - Beta‑blocker eye drops: could interfere with accurate IOP monitoring.